Half-year report 2025 Half-year report 2026 Consolidated financial statements as of 30 June 2026 Half-year report 2026 At a glance Message from the CEO Content Combining Intelligence Activities Note half-year results Financial statements At a…
Half-year report 2025
Half-year report 2026
Consolidated financial statements
as of 30 June 2026
Half-year report 2026
At a glance
Message from the CEO
Content
Combining Intelligence
Activities
Note half-year results
Financial statements
At a glance
2
- Message from the CEO
3
- Combining Intelligence
4
- Activity report first half of FY 2026
5
- Half-year results 2026
10
- Condensed interim consolidated financial statements
19
The creation of this Half-year report reflects our approach to “Combined Intelligence”:
human expertise and teamwork, enhanced by the responsible use of artificial intelligence.
1
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
- At a glance
#12
#10
#13
Healthcare
Sustainable Cities
Consumer
504 mio
480 mio
412 mio
#10
#2
Anchor
280 mio
#12
Life Sciences
Smart Industries
112 mio
507 mio
Results
Balance sheet
H1 2026
H1 2025*
Portfolio result
(mio EUR)
198.8
119.6
Portfolio return %
9.4%
6.7%
Net result (mio EUR)
148.4
85.8
Net return %
7.5%
5.2%
Net result/share
4.0
2.3
H1 2026
FY 2025
(30/06/2026)
(31/12/2025)
Portfolio (mio EUR)
2,407.3
2,120.9
NAV (mio EUR)
2,105.1
2,029.5**
NAV/share
57.2
55.1**
Available liquidity
(mio EUR)
131.4
323.7
- In order to be comparable with the first half of fiscal year 2026, the first half of 2025 has been adapted
to represent the period January to June 2025 (covering Q4 of the fiscal year 2024/25 and Q1 of the fiscal
year 2025).
** Excluding dividend, the NAV as at end FY 2025 amounted to 1,957.7 mio EUR or EUR 53.2/share.
EUR millions per platform portfolio, # number of investments
Growing investment portfolio
2,407
2,121
1,233
1,449
1,523
1,559
Portfolio return
27.0%
1,623
annualized
20.4%
19.1%
19.3%
19.1%
18.8%
2023-24
2024-25
2025
H1 2026
-0.1%
2020-21
03-2021
03-2022
03-2023
03-2024
03-2025
12-2025
2021-22
2022-23
Long term objective
06-2026
Portfolio evolution over >5 years (2021-2026 in EUR millions)
2
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
- Message from the CEO
In the first half of the current financial year, we continued to deliver on our
accelerated growth strategy. Our portfolio expanded to a new record level of more
than EUR 2.4 billion, up EUR 300 million in six months and 50% higher than at the
time of our capital increase in early 2025. In still volatile and uncertain market
conditions, our companies once again demonstrated excellent growth, with both
sales and EBITDA growing by around 10% year-on-year, two thirds of it organic, while
expanding margins. This resilience translated into a solid portfolio return of 9.4%
(or 18.8% annualized), ahead of our annual portfolio return target of 17.5%.
In the first half of the financial year 2026, Gimv generated a net profit of
EUR 148.4 million, or EUR 4 per share, lifting our net asset value by 7.5% to EUR 57.2
per share. We continued to invest in entrepreneurial and innovative companies with
strong long-term growth potential, evidenced by our Anchor investment in Azelis
and the acquisition of Groupe Cap Vert, while maintaining substantial investment
capacity.
Digital and technological transformation have become one of the defining challenges
and opportunities of our time, addressing our economy, our industry and our society
alike, and our companies are no exception. Artificial intelligence and its technologies
propel new insights and applications across companies’ processes. We prepare for a
future where many of our portfolio companies lead this transformation by creating
spearhead solutions across tomorrow’s economic ecosystems. This is where our
Combining Intelligence approach comes in: by pairing entrepreneurial expertise with
AI-enabled capabilities, applications and technologies, we help our portfolio
companies turn this transition into a sustainable competitive advantage.
“Artificial intelligence
and its technologies
propel new insights
and applications
across companies’
processes. We prepare
for a future where our
portfolio companies
lead this transformation
by creating spearhead
solutions across
tomorrow’s economic
ecosystems.”
CEO Koen Dejonckheere
3
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
- Combining Intelligence
Artificial intelligence is rapidly reshaping how decisions are made, how companies
are built, and how value is created. The question is no longer whether to engage
with AI, but how deliberately and how effectively. Gimv’s answer to that question is
captured in two words: Combining Intelligence.
The concept is deliberately simple. The strongest outcomes emerge when human
judgment and artificial intelligence reinforce each other. Human expertise brings
context, relationships, and the kind of nuanced judgment that no model can replicate.
AI brings speed, pattern recognition, and the ability to process information at a scale
no individual can match. Together, they are more powerful than either alone.
This vision operates on two levels. Within Gimv AI-enhanced capabilities are
being systematically embedded across the investment process: from opportunity
screening and due diligence to portfolio monitoring and value creation support. The
objective is to enable investment teams to focus on what they do best: combining
forces with our companies to create sustainable value by realizing above average
growth.
Through and together with its portfolio companies, Gimv is fully engaged to offer
unprecedented digital and tech solutions for society, be it in the fields of R&D and
innovation, the environment, food production, logistics models, manufacturing or
employment.
4
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
- Activity report first half of FY 2026
134
mio EUR
invested
2
new
companies
2
exits
In the first half of 2026, Gimv made two new substantial investments, a new Anchor
position in Azelis and a Sustainable Cities investment in Groupe Cap Vert, and
realized two exits by selling its stake in ALT Technologies and AlpenBlu Clinics.
Across the portfolio, multiple companies advanced their growth strategies through
targeted acquisitions and innovation-driven milestones.
Azelis
Groupe Cap Vert
Belgium / international
France
Gimv Anchor Investments — a joint venture of Gimv and WorxInvest —
acquired a shareholding in excess of 6% in Azelis, a BEL 20-listed global
specialty fine chemicals distributor. With this stake, Gimv Anchor becomes
a top five shareholder in Azelis. The investment reflects Gimv Anchor’s
strategy of backing European champions with a strong competitive
position and an above-average long-term growth potential. Azelis occupies
a high value-add position in a structurally attractive market, with a
business model built around innovation, digital acceleration, sustainability
and targeted M&A. Gimv Anchor will act as a constructive long-term
shareholder, supporting Azelis’s strategic development.
www.azelis.com
Gimv signed an agreement to acquire Groupe Cap Vert, in partnership with
CEO Eric Girot and the management team, with closing expected in the
second half of 2026. Founded in 1984, Cap Vert is France’s leading multispecialist provider of tree and vegetation critical management services, with
nearly 180 mio EUR in revenue, more than 1,200 employees and a nationwide
network of ~60 branches. The Group operates across four centers of
excellence (Trees, Landscaping, Water and Infrastructure) and has built
its platform through more than 18 strategic acquisitions. Cap Vert is well
positioned to benefit from structural tailwinds in urban greening, biodiversity
conservation and climate adaptation, and to act as a natural consolidator in
a highly fragmented sector.
www.groupe-capvert.com
New investments
SUSTAINABLE CITIES
New investments
5
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
ALT Technologies
The Netherlands
Gimv sold its majority stake in ALT Technologies to CCL Industries, the world’s largest label company.
ALT is a global converting company producing die-cut, self-adhesive and printed components for the
automotive industry, a highly complementary fit with CCL’s Automotive, Electronics & Durables activities.
During the partnership with Gimv, ALT expanded its production footprint across Europe and Asia, opened
a new plant for the US market and grew into a global specialist in engineered labels and occupant-safety
components.
www.alt-technologies.com
Les Psy Réunis
SMART INDUSTRIES
Exit
Switzerland
Gimv sold its majority stake in AlpenBlu Clinics
(formerly Les Psy Réunis), a leading outpatient
mental healthcare platform in French-speaking
Switzerland, to Impact Healthcare, the
healthcare investment platform of Swiss familyowned group Après-Demain, alongside the
company’s founders. Since Gimv’s investment
in 2021, the group tripled in size, expanded
its network of specialized care centers across
Geneva, Vaud and Fribourg and invested in
digitalization and governance.
www.lespsyreunis.ch
HEALTHCARE
Exit
6
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
Sofatutor
BioConnection
Equine Care Group
Germany
The Netherlands
Belgium
Sofatutor, a leading German edtech platform
for K-12 students, acquired SchoolMouv, a
French e-learning platform. The acquisition
accelerates Sofatutor’s international
expansion into France and reinforces
the group’s pan-European ambitions.
www.sofatutor.com
BioConnection, a CDMO specializing in the
filling and finishing of injectable drugs, invested
in substantial capacity expansion to support its
continued growth and strengthen its position as
a key manufacturing partner for pharmaceutical
companies.
www.bioconnection.nl
Equine Care Group entered the US market
through the acquisition of Salado Equine
Medical Center, marking an important further
internationalization step for the specialist
equine veterinary platform.
www.equinecaregroup.com
CONSUMER
Portfolio
HEALTHCARE
Portfolio
HEALTHCARE
Portfolio
Quality Guard
Belgium
Quality Guard, a leading provider of digital food safety and HACCP compliance software serving more
than 9,000 customers across Europe, acquired Kooklin, a French food safety software company with a
leading position in the French market. This is the second acquisition since Gimv joined Quality Guard
as strategic partner in November 2025, consistent with the shared ambition to consolidate Europe’s
fragmented food safety software market.
www.qualityguard.eu
CONSUMER
Portfolio
7
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
Metis Group
Cegeka
The Netherlands
Belgium
The combination of Variass and AME into Metis Group was successfully
finalized, creating a strengthened platform in electronics manufacturing
services (EMS) with complementary capabilities and customer bases.
www.metisgroup.eu.
Cegeka further engages in our digital and AI enabled society. It welcomed
Koen Deryckere as its new Chief Executive Officer. Deryckere joins from
Accenture, where he served as CEO and President for France and the
Benelux and was a member of the Global Management Committee, bringing
extensive experience in driving growth and leading large international
organizations.
Cegeka acquired the Swiss industry specialist Lean Projects, strengthening
its ERP and industrial automation capabilities in Switzerland, and the
Belgian cybersecurity firm 3Point, bringing strong expertise in defense and
public safety environments.
Cegeka also entered a strategic partnership with KEYES to launch Belgian
Critical Cloud, a sovereign cloud proposition targeting government, defense
and critical infrastructure operators that require full Belgian data residency
and independence from foreign legislation.
www.cegeka.com
SMART INDUSTRIES
Portfolio
Hemink
The Netherlands
Hemink Groep, a specialist in institutional home improvement programs,
continued its buy-and-build strategy with two acquisitions. Camp, a nearly
50-year-old specialist in façade maintenance and painting works in South
Netherlands, extends Hemink’s nationwide coverage to a fourth region.
Instain, a specialist in installation technology, further broadens Hemink’s
one-stop-shop offering and strengthens the group’s capacity to support
clients across the full real estate lifecycle.
www.heminkgroep.nl
Portfolio
SUSTAINABLE CITIES
Portfolio
Portfolio
8
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
Following the strategic decision to discontinue new Life Sciences investments (January 2026),
Gimv continues to actively support its existing Life Sciences portfolio companies.
Kinaset Therapeutics
Complement Therapeutics
USA
UK
Gimv supported Kinaset Therapeutics in completing an oversubscribed
103 mio USD Series B financing to advance its novel inhaled therapeutic
candidate for respiratory diseases.
www.kinaset.com
Complement Therapeutics achieved two significant clinical milestones in the
first half of 2026. CTx001, its lead programme for Geographic Atrophy (a severe
form of age-related macular degeneration) received FDA Fast Track Designation
in January, accelerating its path to potential approval. In May, the company
completed dosing of the first patient cohort in the Phase I/II Opti-GAIN study,
with an independent data monitoring committee recommending continuation
of the trial.
www.complementtx.com
Portfolio
LIFE SCIENCES
Portfolio
Portfolio
LIFE SCIENCES
Portfolio
Biotalys
Kivu Bioscience
USA
Belgium
Kivu Bioscience announced the dosing of the first patient in its Phase 1 trial
of KIVU-107, a next-generation PTK7-targeting antibody-drug conjugate (ADC)
for advanced solid tumors.
www.kivubioscience.com
Gimv participated in a 12.05 mio EUR private placement in Biotalys to
support continued product development and the company’s path toward
commercialization, following EPA approval in the US for EVOCA™, its first
protein-based biofungicide. An EU approval process is currently ongoing,
Portfolio
with an outcome expected in 2026.
www.biotalys.com
LIFE SCIENCES
Portfolio
LIFE SCIENCES
Portfolio
9
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
- Half-year results 2026
In this section of our half-year report, we report our financial performance using our
Investment Basis, providing a “look through” of the IFRS statements to present the
underlying performance of our companies (see explanation in our FY 2025 annual
report). As explained in the Reconciliation of Investment basis and IFRS section
below, the total comprehensive income and Net Asset Value are the same under our
audited IFRS financial statements and our Investment basis. We believe this is more
transparent to the readers of our annual report.
Our Investment Basis itself is an Alternative Performance Measure (APM). Further
information about our APM’s can be found at the end of our financial statements and
should be read alongside the Investment basis to IFRS reconciliation.
Performance: Gimv companies continue to deliver strong growth
performance
Portfolio result (mio EUR)
Portfolio return %
Net result (mio EUR)
Net return on equity %
Net result/share (on an weighted basis)
H1 2026
H1 2025
198.8
9.4%
148.4
7.5%
4.0
119.6
6.7%
85.8
5.2%
2.3
In order to be comparable with the first half of fiscal year 2026, the first half of 2025
has been adapted to represent the period January to June 2025 (covering Q4 of the
fiscal year 2024/25 and Q1 of the fiscal year 2025).
Sales growth by platform (mio EUR)
Ebitda growth by platform (mio EUR)
+12%
+8%
2,000
200
1,500
150
1,000
100
500
50
0
Consumer
H1 2025
Healthcare
H1 2026
Smart
Industries
Sustainable
Cities
Total
0
Consumer
H1 2025
Healthcare
Smart
Industries
Sustainable
Cities
Total
H1 2026
10
Half-year report 2026
At a glance
Message from the CEO
In still volatile and uncertain market circumstances, the companies in our four
platforms (Consumer, Healthcare, Smart Industries and Sustainable Cities) once
again have delivered a growth performance in the first half of 2026 above the overall
Economic growth. Year-to-date figures for 2026 show a sales growth of 8% and a
growth in EBITDA of 12% versus the comparable period in 2025, demonstrating
expanding margins. Both for sales and EBITDA, two thirds of this growth originate
from organic expansion.
In the first half of 2026, our companies in the Smart Industries platform could benefit
from the transition towards improving industrial market conditions by end 2025/early
2026. Companies in both the Consumer and Healthcare platform could continue to
expand their margins, with growth in EBITDA outpacing sales expansion. Finally, some
companies in the Sustainable Cities platform were somewhat negatively impacted in
the first months of the year by adverse weather circumstances, but are clearly picking
up the growth trend again in the last months of the first half of 2026.
The sustained growth performance of our companies in the first half of 2026 has led
to a total portfolio result of 199 mio EUR, or a non-annualized portfolio return of 9.4%.
On an annualized basis, this represents a portfolio return of 18.8%, above our annual
target of at least 17.5%. The average EBITDA multiple used to measure the fair value
of our companies under IFRS remained stable versus the end of 2025 at 9.7x. The
average calibration effect on the multiples used evolved from -17% end December
2025 to -16% at the end of June 2026.
Portfolio return (in %)
27.0%
annualized
20.4%
19.1%
19.3%
19.1%
18.8%
-0.1%
2020-21
2021-22
2022-23
2023-24
2024-25
2025
H1 2026
Long term objective
Combining Intelligence
Activities
Note half-year results
Financial statements
The positive valuation result was mainly determined by the strong operational results
of our companies, with growth in EBITDA having a positive valuation impact of 196.3
mio EUR, once again showing evidence that growth in operating profitability is the
main contributor to the total portfolio result of 199 mio EUR.
Thanks to the strong portfolio result, Gimv’s net profit for the first half of 2026 amounts
to 148.4 mio EUR or EUR 4 per share. This translates into a non-annualized net return
on equity of 7.5%, an increase versus the net return comparable period in 2025.
Portfolio: Maintained growth acceleration of the portfolio, expanding to
an all-time high of more than 2.4 billion EUR
Investments and exits
H1 2026
H1 2025
Investments (mio EUR)
Exit proceeds (mio EUR)
134.0
42.0
226.4
369.7
During the first half of the financial year 2026, Gimv invested 134 mio EUR. Through
Gimv Anchor Investments, Gimv acquired a shareholding of more than 6% in Azelis,
becoming one of the company's largest long-term shareholders. In addition, Gimv
signed an agreement to acquire Groupe Cap Vert, the French leader in tree and
vegetation management services, a highly complementary addition to the Sustainable
Cities platform portfolio. When adding this investment to the portfolio (closing is
expected in September 2026), the total portfolio value exceeds 2.5 billion EUR.
Alongside these new investments, Gimv continued to actively support the development
of its existing portfolio companies. Across the portfolio, companies continued to
execute on their value creation plans through targeted acquisitions, international
expansion, capacity investments and innovation-driven milestones. Examples include
acquisitions by Sofatutor, Quality Guard, Hemink, Equine Care Group and Cegeka as
well as BioConnection's manufacturing capacity expansion.
Including follow-on investments, Gimv invested a total of 134 mio EUR during the first
six months of the financial year. During the same period, Gimv realized the exits of
ALT Technologies and AlpenBlu Clinics (formerly Les Psy Réunis). Total proceeds from
portfolio exits amounted to 42 mio EUR, generating 15.5 mio EUR of realized capital
gains.
11
Half-year report 2026
At a glance
Message from the CEO
As of 30 June 2026, Gimv's core investment portfolio across its four investment
platforms and Gimv Anchor Investments amounted to 2.2 billion EUR. Including the
remaining Life Sciences portfolio (4.6% of the total portfolio value) and Infravest (4%
of the total portfolio value), the total investment portfolio reached 2.4 billion EUR.
The core portfolio comprises 49 companies. Gimv also continues to actively manage
10 remaining Life Sciences companies, following the strategic decision to discontinue
new investments in the sector. The portfolio remains well diversified, with the ten
largest investments representing 50.3% of total portfolio value and no individual
investment representing more than 10% of the total portfolio value.
Portfolio composition (mio EUR)
2,121
103
109
277
Activities
Note half-year results
Equity and liquidity: Persistent strong equity growth
NAV (mio EUR)
NAV/share
Liquidity (mio EUR)
480
418
Infra and others
Life Sciences
503
FY 2025
2,105.1
57.2
131.4
2,029.5
55.1
323.7
After payment of the dividend (EUR 1.95 per share) for the previous financial year
2025 and including the net profit of the first half of the financial year 2026 (EUR 4 per
share), the net equity value grew with 7.5% to EUR 57.2 per share at the end of June
2026. Gimv’s total net equity value further grew to 2,105.1 mio EUR at the end of June
2026.
Loan to Value ration (in mio EUR)
507
504
H1 2026
This liquidity is partly financed by bonds (350 mio EUR), resulting in a negative net
cash on the balance sheet of -216 mio EUR. In other words, the equity of Gimv is more
than fully invested in the portfolio. Right after the end of the first half of the current
fiscal year, 75 mio EUR of the outstanding bonds have been repaid, bringing the
current amount of bond financing to 275 mio EUR and the availliquidity to 456.4 mio
EUR.
165
454
Financial statements
Taking into account the cash impact of the dividend (71.8 mio EUR), investments of
134 mio EUR and exit proceeds of 42 mio EUR, Gimv’s liquidity and investment capacity
remained intact at a total level of 531.4 mio EUR, of which 131.4 mio EUR cash on the
balance sheet and a 400 mio EUR undrawn revolving credit facility. The latter has
been renegotiated and doubled in the first quarter of 2026.
2,407
115
112
Combining Intelligence
Anchor
Sustainable Cities
Total assets
Cash and cash equivalents
Total net assets
Total Financial Indebtedness
Total Net debt / (net cash)
Loan to Value ratio (total net debt / total net assets)
30-06-2026
31-12-2025
2,558.6
131.4
2,427.1
358.8
227.4
9.4%
2,464.7
323.7
2,141.0
355.9
32.2
1.5%
Smart Industries
Healthcare
369
31-12-2025
412
Consumer
30-06-2026
12
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
Sustainability: a lever for value creation
Key events after 30/06/2026
Gimv continues to deepen the integration of sustainability across its investment
process, with an increasing focus on translating sustainability into long-term value
creation. During the first half of the year, Gimv developed the first platform-specific
sustainability value creation blueprint, supported by initial proof points demonstrating
how sustainability can create commercial, operational and strategic value across the
portfolio.
The valuation of our portfolio is based on market multiples as at the end of June
2026. Since then, we have closely followed the evolution of the stock markets. To
date, we have not noticed any evolution in market multiples that indicates that
our valuation should be adjusted.
On July 5 2026, Gimv repaid 75 mio EUR of its outstanding bonds, bringing the
total amount of outstanding bonds to 275 mio EUR.
Mid-August, Spineart announces that the BAGUERA® C cervical disc has
received FDA approval for 1 and 2 contiguous levels, expanding access in the
United States to a motion-preserving solution for patients suffering from cervical
disc disease. This news might have a positive impact on the future valuation of
Spineart.
In August, Gimv sold its stake in the Swiss group of Medical Practices MVZ
Holding without impact on the Net Asset Value.
Gimv creates the function of “Chief Digital Transformation” at the level of its
executive committee. Meanwhile, this position has been filled with an external
international profile. The new member of the executive committee will be
presented later.
Tom Van de Voorde, Platform Head of Smart Industries, has decided to leave
Gimv. We want to thank Tom for 19 years of fruitful collaboration and Building
Leading Companies together. We wish him all the best with his future
endeavours. Information regarding the succession will be communicated later.
Building on this foundation, Gimv continues to support its portfolio companies in their
decarbonisation ambitions through a pragmatic, company-specific approach. By
helping companies measure greenhouse gas emissions, establish reduction targets
and identify value-creating decarbonisation initiatives, Gimv strengthens both
resilience and long-term competitiveness.
13
Half-year report 2026
At a glance
Message from the CEO
Reconciliation of Investment Basis and IFRS
Gimv makes investments in portfolio companies directly, held by Gimv NV or its
consolidated subsidiaries, and, as of fiscal year 2025, indirectly, held through
intermediate holding companies (“Investment entity subsidiaries”). The application of
IFRS 10 requires us to fair value the intermediate holding companies instead of
consolidating them line-by-line. This fair value approach, applied at the intermediate
holding company level, obscures portfolio performance, since the financial effect of
the underlying portfolio companies is aggregated into a single (fair) value of the
investment entity subsidiary as included in our total investment portfolio (under
IFRS 10). Other (income and cost) items associated with the investment entity
subsidiaries (which would be eliminated in a consolidation) are now included
separately.
IFRS basis of consolidation
Combining Intelligence
Note half-year results
Financial statements
To maintain transparency and help the understanding of the performance of our
portfolio, we introduced a separate non-GAAP “Investment basis” (in line with our
previous financial reporting). This review of our annual results is prepared using the
Investment basis as we believe it provides a more understandable view of our
performance. The net profit and the Net Asset Value are equal under the Investment
basis and IFRS. The Investment basis is simply a “look through” of IFRS 10 to present
the underlying performance and safeguards the consistency of our financial reporting
with prior years.
A reconciliation of the Consolidated Statements (Comprehensive Income, Financial
Position and Cash Flow Statement) from Investment basis to IFRS basis is shown on
the following pages.
Investment basis of consolidation
NV
Directly held portfolio
companies
Activities
NV
Consolidated
subsidiaries
(investment related
services)
Investment entity
subsidiaries
Directly held portfolio
companies
Portfolio companies
Directly held portfolio
companies
Consolidated
subsidiaries
(investment related
services)
Investment entity
subsidiaries
Directly held portfolio
companies
Portfolio companies
Consolidated
Fair valued
Portfolio companies included in fair value of investment entity subsidiaries
14
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
Reconciliation of the consolidated statement of profit & loss and other comprehensive income for the first semester of financial year 2026
Consolidated statement of profit & loss and other comprehensive income
(in 1,000 EUR)
Realised profits/(losses) on disposal of investments
Unrealised profits/(losses) on the revaluation of investments
Fair value movements on investment entity subsidiaries
Dividend income
Portfolio result: profit (loss)
Management, director and other fees
Income from investment entity subsidiaries
Other operating income
Services and other goods
Employee benefits - remuneration
LTIP benefits
Amortisation and depreciation
Other operating expenses
Operating profit
Finance income
Profit before financing and income taxes
Finance costs
Profit before tax
Corporate income tax
Net profit for the period
Minority result
Net profit for the period of the group
Other comprehensive income
Actuarial gains (losses) on defined benefit plans
Total comprehensive income (loss) for the period of the group
Investment basis
IFRS adjustments
IFRS basis
Investment basis
IFRS adjustments
IFRS basis
30/06/2026
30/06/2026
30/06/2026
30/06/2025
30/06/2025
30/06/2025
15,530
183,269
198,799
1,044
1,504
-7,769
-14,932
-12,118
-1,431
-4,777
160,320
2,443
162,763
-5,341
157,422
-921
156,501
8,166
148,335
148,335
-100,745
87,244
-13,501
3,554
882
899
-8,166
-8,166
-8,166
-8,166
-8,166
15,530
82,524
87,244
185,298
1,044
3,554
1,504
-6,887
-14,932
-12,118
-1,431
-3,878
152,154
2,443
154,597
-5,341
149,256
-921
148,335
148,335
148,335
63,878
55,694
43
119,615
725
489
-9,814
-11,702
-8,553
-1,367
-3,581
85,812
6,945
92,757
-5,342
87,415
-278
87,137
1,335
85,802
-86
85,716
-12,607
6,026
-6,581
1,224
3,005
562
-1,790
-13
-1,803
468
-1,335
-1,335
-1,335
63,878
43,087
6,026
43
113,034
725
1,224
489
-6,809
-11,702
-8,553
-1,367
-3,019
84,022
6,932
90,954
-4,874
86,080
-278
85,802
85,802
-86
85,716
15
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
Reconciliation of the consolidated statement of financial position per 30 June 2026
Consolidated statement of financial position (in 1,000 EUR)
Non-current assets
Investment portfolio
Direct investments
Investments in investment entity subsidiaries
Intangible assets
Property, plant and equipment
Current assets
Trade and other receivables
Cash and cash equivalents
Marketable securities
Other current assets
Total assets
Equity
Equity - group share
Issued capital
Share premium
Reserves
Non controlling interests
Liabilities
Non-current liabilities
Bonds
Lease liabilities
LTIP liabilities
Provisions
Current liabilities
Bonds
Lease liabilities
LTIP liabilities
Trade and other payables
Other liabilities
Total equity and liabilities
Investment basis
IFRS adjustments
IFRS basis
Investment basis
IFRS adjustments
IFRS basis
30/06/2026
30/06/2026
30/06/2026
31/12/2025
31/12/2025
31/12/2025
2,423,162
2,407,346
2,407,346
319
15,497
135,394
2,420
131,415
-18,856
-18,856
-857,792
838,936
1,606
1,800
-194
-17,250
-16,971
-16,971
-1,247
-968
-279
-10
-269
-17,250
2,404,306
2,388,490
1,549,554
838,936
319
15,497
137,000
4,220
131,221
1,559
2,541,306
2,105,057
2,105,057
345,460
369,449
1,390,148
436,249
341,759
275,000
7,909
56,913
1,937
94,490
83,827
1,636
740
5,506
2,781
2,541,306
2,137,840
2,120,943
2,120,943
372
16,524
326,878
1,902
173,199
150,534
1,243
2,464,718
2,037,302
2,029,483
345,460
369,449
1,314,574
7,819
427,416
331,726
275,000
8,623
46,166
1,937
95,689
80,855
1,687
1,328
9,022
2,797
2,464,718
-7,972
-7,972
-757,073
749,101
-331
-331
-8,303
-7,819
-7,819
-483
2,129,868
2,112,971
1,363,870
749,101
372
16,524
326,547
1,902
172,868
150,534
1,243
2,456,415
2,029,483
2,029,483
345,460
369,449
1,314,574
426,932
331,726
275,000
8,623
46,166
1,937
95,206
80,855
1,687
1,328
8,931
2,405
2,456,415
1,559
2,558,556
2,122,028
2,105,057
345,460
369,449
1,390,148
16,971
437,496
342,727
275,000
7,909
56,913
1,937
94,769
83,827
1,636
740
5,516
3,050
2,558,556
-483
-91
-392
-8,303
16
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
Reconciliation of the consolidated cash flow statement for the first semester of financial year 2026
Consolidated cash flow statement (in 1,000 EUR)
Cash flow from operating activities
Investments
Proceeds from investments
Investments in investment entity subsidiaries
Proceeds from investment entity subsidiaries
Interest received from investments
Dividend received from investments
LTIP benefits
Short term bridge loan investment
Management fees from managed funds
Remuneration and other benefits to employees and directors
Paid/recovered CIT and other taxes
Other operating expenses
Cash flow from investing activities
Interest received on cash deposits
Purchases of property, plant and equipment
Other cash flows from investment activities
Cash flow from financing activities
Capital and share premium increase, gross
Paid costs related to capital and share premium increase
Paid interest and fees on cash deposits and credit lines
Dividends to shareholders
Purchase own shares
Sale own shares
Other cash flow from financing activities
Change in cash during period
Cash at beginning of period
Acquired not yet received interest on deposits and other investments
Cash at end of period
Investment basis
30/06/2026
IFRS adjustments
30/06/2026
IFRS basis
30/06/2026
Investment basis
30/06/2025
IFRS adjustments
30/06/2025
IFRS basis
30/06/2025
-121,058
-137,199
49,392
370
-2,036
-18,406
-2,642
-10,537
3,916
2,530
-218
1,604
-75,242
-3,917
-71,781
-3,486
2,574
1,368
-192,384
323,733
66
131,415
137
56
-5,719
3,710
738
1,352
137
-331
-194
-120,921
-137,143
49,392
-5,719
3,710
370
-2,036
-18,406
-1,904
-9,185
3,916
2,530
-218
1,604
-75,242
-3,917
-71,781
-3,486
2,574
1,368
-192,247
323,402
66
131,221
53,988
-171,628
301,673
517
44
-31,470
-14,874
78
-15,465
-918
-13,969
1,034
2,410
-722
-654
233,907
246,794
-3,951
-2,545
-6,282
-6,008
5,213
686
288,929
285,703
574,632
-750
103,288
-517
-105,703
185
1,997
-750
-750
53,238
-68,340
301,156
-105,703
517
44
-31,470
-14,874
78
-15,465
-733
-11,972
1,034
2,410
-722
-654
233,907
246,794
-3,951
-2,545
-6,282
-6,008
5,213
686
288,179
285,703
573,882
17
Half-year report 2026
At a glance
Message from the CEO
Notes to the reconciliation of consolidated statement of comprehensive income:
Combining Intelligence
Activities
Note half-year results
Financial statements
2 Intercompany balances between Investment entity subsidiaries and consolidated subsidiaries
1 Applying IFRS 10 to the Consolidated statement of comprehensive income consolidates the line
also impact the transparency of our results under the IFRS basis. If an Investment entity
items of a number of investment subsidiaries (related to the 2024 LTIP vintage) into a single line
subsidiary has an intercompany balance with a consolidated subsidiary of the Group, then the
item “Fair value movements on investment entity subsidiaries”. In the “Investment basis”
asset or liability of the Investment entity subsidiary will be aggregated into its fair value, while
accounts we have disaggregated these line items to analyse our total return as if these
the asset or liability of the consolidated trading subsidiary will be disclosed as an asset or
Investment entity subsidiaries were fully consolidated, providing a look-through up to the
liability in the Consolidated statement of financial position.
portfolio companies level, consistent with prior years. The adjustments simply reclassify the
Consolidated statement of comprehensive income of the Group, and the net result is equal
under the Investment basis and the IFRS basis.
2 Realised profits, unrealised profits and portfolio income shown in the IFRS accounts only relate
3 Investment basis financial statements are prepared for performance measurement and therefore
reserves are not analysed separately under this basis.
Notes to the reconciliation of Consolidated cash flow statement:
to portfolio companies that are held directly by the Group and not those portfolio companies
1 The Consolidated cash flow statement is impacted by the application of IFRS 10 as cash flows
held through Investment entity subsidiaries. Realised profits, unrealised profits and portfolio
to and from Investment entity subsidiaries are disclosed, rather than the cash flows to and from
income in relation to portfolio companies held through Investment entity subsidiaries are
the underlying portfolio. Therefore in our Investment basis financial statements, we have
aggregated into the single line “Fair value movement on investment entity subsidiaries”. This is
disclosed our cash flow statement on a “look through” basis, in order to reflect the underlying
the most significant reduction of information in our IFRS accounts.
sources and uses of cash flows and disclose the underlying investment activity.
3
Other items also aggregated into the line “Fair value movements on investment entity
subsidiaries” include operating expenses or income, interest income or expenses, and LTIP.
2 There is a difference between the change in cash and cash equivalents of the Investment basis
financial statements and the IFRS financial statements because there are cash balances held in
Investment entity subsidiaries. Cash held within Investment entity subsidiaries will not be shown
Notes to the reconciliation of consolidated statement of financial position:
in the IFRS statements but are represented in the Investment basis statements.
1 Applying IFRS 10 to the Consolidated statement of financial position aggregates the line items
into the single line item “Investments in investment entity subsidiaries”. In the Investment basis
we have disaggregated these items to analyse our net assets as if the Investment entity
subsidiaries were consolidated. The adjustment reclassifies items in the Consolidated statement
of financial position. There is no change to the net assets, although for reasons explained below,
gross assets and gross liabilities are different. The disclosure relating to portfolio companies is
significantly reduced by the aggregation, as the fair value of all investments held by Investment
entity subsidiaries is aggregated into the “Investments in investment entity subsidiaries” line.
We have disaggregated this fair value and disclosed the underlying portfolio holding in the
relevant line item 'Direct investments'. Other items which may be aggregated include LTIP, other
assets and other payables, and the Investment basis presentation again disaggregates these
items.
18
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
- Condensed interim consolidated financial statements
General information
Name
Legal form
Country of domiciliation
Registered office
Date of incorporation:
Country of incorporation
LEI code
Enterprise number
Main geographic area of activity
Description of main activities
Website
Name of parent company
Name of the ultimate parent of the group
Change in name or other identifiers since end
Gimv
NV (public limited company)
Belgium
Karel Oomsstraat 37, 2018 Antwerp
25 February 1980
Belgium
549300UFHGFY5IOON989
BE 0220.324.117
Belgium – The Netherlands – France – DACH Region
Investment company
www.gimv.com
Gimv
Gimv
None of the previous reporting period
19
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
The interim consolidated financial statements as of 30 June 2026 have not been audited. The statutory auditor has conducted a review of these interim consolidated statements
as of 30 June 2026, a review is less extensive than a full year-end audit. The comparative figures as of 30 June 2025 have also not been audited, but the comparative figures as
of 31 December 2025 have been audited.
- Interim consolidated statement of financial position
Consolidated statement of financial position (in 1,000 EUR)
Non-current assets
Investment portfolio
Direct investments
Investments in investment entity subsidiaries
Intangible assets
Property, plant and equipment
Current assets
Trade and other receivables
Cash and cash equivalents
Marketable securities
Other current assets
Total assets
Equity
Equity - group share
Issued capital
Share premium
Reserves
Liabilities
Non-current liabilities
Bonds
Lease liabilities
LTIP liabilities
Provisions
Current liabilities
Bonds
Lease liabilities
LTIP liabilities
Trade and other payables
Other liabilities
Total equity and liabilities
Note
3
3
3
4
4
5
5
7
7
8
8
7
7
8
30/06/2026
31/12/2025
2,404,306
2,388,490
1,549,554
838,936
319
15,497
137,000
4,220
131,221
1,559
2,541,306
2,129,868
2,112,971
1,363,870
749,101
372
16,524
326,547
1,902
172,868
150,534
1,243
2,456,415
2,105,057
2,105,057
345,460
369,449
1,390,148
436,249
341,759
275,000
7,909
56,913
1,937
94,490
83,827
1,636
740
5,506
2,781
2,541,306
2,029,483
2,029,483
345,460
369,449
1,314,574
426,932
331,726
275,000
8,623
46,166
1,937
95,206
80,855
1,687
1,328
8,931
2,405
2,456,415
The Notes to the financial statements form an integral part of these interim consolidated financial statements.
20
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
- Interim consolidated statement of profit or loss and other comprehensive income
Consolidated statement of profit or loss and other comprehensive income (in 1,000 EUR)
Realised profits/(losses) on disposal of investments
Unrealised profits/(losses) on the revaluation of investments *
Fair value movements on investment entity subsidiaries
Dividend income
Portfolio result: profit (loss)
Management, director and other fees
Income from investment entity subsidiaries
Other operating income
Services and other goods
Employee benefits - remuneration
LTIP benefits
Amortisation and depreciation
Other operating expenses
Operating profit
Finance income
Profit before financing and income taxes
Finance costs
Profit before tax
Corporate income tax
Net profit for the period
Net profit for the period of the group
Other comprehensive income
Actuarial gains (losses) on defined benefit plans
Total comprehensive income (loss) for the period of the group
Note
30/06/2026
30/06/2025
15,530
82,524
87,244
185,298
1,044
3,554
1,504
-6,887
-14,932
-12,118
-1,431
-3,878
152,154
2,443
154,597
-5,341
149,256
-921
148,335
148,335
148,335
63,878
43,087
6,026
43
113,034
725
1,224
489
-6,809
-11,702
-8,553
-1,367
-3,019
84,022
6,932
90,954
-4,874
86,080
-278
85,802
85,802
-86
-86
85,716
Note
30/06/2026
30/06/2025
11
11
4.03
4.03
2.33
2.33
9
10
10
10
As from this financial year, “Interest income” is no longer presented as a separate line item but embedded in the line item “Unrealised profits/(losses) on the revaluation of investments.
Earnings per share (in EUR)
Basic earnings per share
Diluted gains earnings per share
The Notes to the financial statements form an integral part of these interim consolidated financial statements.
21
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Issued
capital
Share
premium
Retained
earnings
Actuarial gains
(losses) DB
pension plans
Financial statements
- Interim consolidated statement of changes in equity
30/06/2026 (in 1,000 EUR)
Note
01/01/2026
Treasury
Shares
Total equity
2,029,483
345,460
369,449
1,313,823
751
Net profit for the period of the group
148,335
148,335
Total comprehensive income (loss) for the period of the group
148,335
148,335
Dividends to shareholders
7
-71,781
-71,781
Net purchase / sale own shares
5
-979
-979
345,460
369,449
1,390,377
751
-979
2,105,057
Issued
capital
Share
premium
Retained
earnings
Actuarial gains
(losses) DB
pension plans
Treasury
Shares
Total equity
271,619
158,660
1,208,315
809
-407
1,638,996
85,802
85,802
-86
-86
85,802
-86
85,716
246,794
30/06/2026
30/06/2025 (in 1,000 EUR)
Note
01/01/2025
Net profit for the period of the group
Other comprehensive income
10
Total comprehensive income (loss) for the period of the group
Capital increase
7
67,886
178,908
Cost of capital increase
7
-3,951
-3,951
Dividends to shareholders
7
-92,995
-92,995
Net purchase / sale own shares
Other changes
30/06/2025
5
335,554
337,568
-1,056
15
1,200,081
723
407
-649
15
1,873,926
The Notes to the financial statements form an integral part of these interim consolidated financial statements.
22
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
- Interim consolidated cash flow statement (direct method)
Consolidated cash flow statement (in 1,000 EUR)
Cash flow from operating activities
Investments
Proceeds from investments
Investments in investment entity subsidiaries
Proceeds from investment entity subsidiaries
Interest received from investments
Dividend received from investments
LTIP benefits
Short term bridge loan investment
Management fees from managed funds
Remuneration and other benefits to employees and directors
Paid/recovered CIT and other taxes
Other operating expenses
Note
3
3
3
8
8;10
10
Cash flow from investing activities
Interest received on cash deposits
Purchases of property, plant and equipment
Other cash flows from investment activities
Cash flow from financing activities
30/06/2026
30/06/2025
-120,921
-137,143
49,392
-5,719
3,710
370
-2,036
-18,406
-1,904
-9,185
53,238
-68,340
301,156
-105,703
517
44
-31,470
-14,874
78
-15,465
-733
-11,972
3,916
2,530
-218
1,604
1,034
2,410
-722
-654
-75,242
233,907
Capital and share premium increase, gross
5
246,794
Paid costs related to capital and share premium increase
Paid interest and fees on cash deposits and credit lines
Dividends to shareholders
Purchase own shares
Sale own shares
Other cash flow from financing activities
Change in cash during period
Cash at beginning of period
Acquired not yet received interest on deposits and other investments
Cash at end of period
5
7
6
-3,917
-71,781
-3,486
2,574
1,368
-192,247
323,402
66
131,221
-3,951
-2,545
-6,282
-6,008
5,213
686
288,179
285,703
573,882
The Notes to the financial statements form an integral part of these interim consolidated financial statements.
23
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
Notes to the condensed consolidated interim financial statements
1.
Basis of preparation and accounting policies
1.1
Declaration of conformity and accounting standards
Gimv NV is a public limited company incorporated under Belgian law and listed on Euronext Brussels. Its registered office is at Karel Oomsstraat 37, 2018 Antwerp. The interim
consolidated financial statements cover a six-month period ending on 30 June 2026 and comprise the financial statements of Gimv NV and its consolidated subsidiaries
(collectively, “the Group”). These statements were prepared in accordance with IAS 34 – Interim Financial Reporting and were approved by the Board of Directors on 1 September
2026.
The Group shortened its reporting period to nine months in the previous financial year, ending on 31 December 2025. The shortening of the financial year resulted from the
decision to change the financial year-end in order to align it with the calendar year. As a consequence the comparative figures as per 30 June 2025 are calculated on the basis
of the fourth quarter of financial year 2024-2025 and the first quarter of financial year 2025, combined to provide a comparable period from 1 January 2025 to 30 June 2025.
There are no changes in the accounting policies and estimates used compared to the financial statements for the 2025 financial year.
The condensed interim financial statements have been drawn up in accordance with the International Financial Reporting Standards (IFRS) as adopted in the European Union and
that they give a true and fair view of the equity and financial situation of the Group at 30 June 2026, and of its results and cash flows for the six months ending on that date.
The condensed interim financial statements do not contain all the information required for full reporting and must be read together with the annual report on the consolidated
financial statements ended as of 31 December 2025. The condensed interim financial statements are prepared to the nearest EUR 1,000.
Applied new and amended standards
During this period, the Group has applied all new and revised Standards and Interpretations issued by the International Accounting Standards Board (IASB) and the International
Financial Reporting Interpretations Committee (IFRIC) of the IASB, as endorsed by the EU, and effective for the financial year starting 1 January 2026.
The following new and revised standards and interpretations issued by the IASB and IFRIC and as endorsed by the EU are effective for this period:
Amendments to IFRS 9 and IFRS 7 - Classification and Measurement of Financial Instruments the other amendments relate to IFRS 9 and IFRS 7 - clarifying application of the
cash-flow criterion for ESG-linked loans
Annual Improvements to IFRS Accounting Standards - Volume 11; the Amendments provide limited changes that clarify wording or correct minor unintended consequences
and are effective for annual periods beginning on or after 1 January 2026.
The application of these new standards, interpretations and amendments has had no material influence on the consolidated financial statements of the Group.
24
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
Standards with effect after the balance sheet date
The Group has not early adopted the following new and amended standards, which take effect after 30 June 2026, namely:
IFRS 18 - Presentation and Disclosure in Financial Statements (applicable for annual periods beginning on or after 1st January 2027)
Amendments to IAS 21 – Translation to a Hyperinflationary Presentation Currency; (applicable for annual periods beginning on or after 1st January 2027 but not yet endorsed
in the EU)
Amendments to the Fair Value Option in IAS 28 Investments in Associates and Joint Ventures (applicable for annual periods beginning on or after 1st January 2027 but not
yet endorsed in the EU)
The Group is still assessing the impact of IFRS 18 and will apply the new standard from its mandatory effective date of 1 January 2027. Retrospective application is required, and
so the comparative information for the financial year ending 31 December 2026 will be restated in accordance with IFRS 18.
The future application of the other new and amended standards is not expected to have a material impact on the Group’s consolidated financial statements.
1.2
Going concern
These condensed interim financial statements have been prepared on a going concern basis. The Board of Directors have made an assessment of going concern for a period of
at least 12 months from the date of approval of the accounts, taking into account the Group’s current performance, financial position and the principal and emerging risks facing
the business.
1.3
Consolidation principles
The consolidated financial statements contain the financial details of the parent Gimv NV (the “Company”) and its fully consolidated subsidiaries (the “Group”). All subsidiaries
close their annual accounts on 31 December.
Exemption from the consolidation obligation for investment entities
In accordance with IFRS 10 Consolidated Financial Statements, the Company qualifies as an investment entity. As a result, the Company applies the investment entity exemption
set out in IFRS 10.27 and does not consolidate subsidiaries that qualify as investment entities themselves.
An investment entity is defined as an entity that:
obtains funds from one or more investors for the purpose of providing investment management services;
has a business purpose of generating returns from capital appreciation, investment income, or both; and
measures and evaluates the performance of substantially all of its investments on a fair value basis.
The Company meets all of these criteria. Consequently, only subsidiaries whose purpose and business consist in providing services that relate to the Company’s investment
activities, and that are not investment entities themselves, are fully consolidated. These subsidiaries are fully consolidated from the date on which the Group effectively obtains
control. All Intra-group balances and transactions are eliminated upon consolidation. These subsidiaries are de-consolidated from the date that control ceases.
25
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
All other investee entities are measured at fair value through profit or loss (FVTPL) in accordance with IFRS 9, rather than being fully consolidated. This includes:
investments in investment entity subsidiaries;
direct investments in entities over which the Group has majority control (‘subsidiaries’); and
direct investments in entities over which the Group exercises significant influence on financial and business decisions but does not have majority control (‘associates’).
The Group comprises different types of subsidiaries. For a new subsidiary, the Group assesses whether it qualifies as an investment entity under IFRS 10, based on the function
the entity performs within the Group. For existing subsidiaries, the Group annually reassesses the function performed by each type of subsidiary to determine if the treatment
under IFRS 10 exception from consolidation is still appropriate.
We refer to Note 12 where all consolidated subsidiaries, investment entities and active portfolio companies have been listed.
Investments in investment entity subsidiaries
Investments in investment entity subsidiaries are controlled subsidiaries whose main purpose is to hold investments. These entities are typically intermediate investment holding
structures which hold the Group’s interests in investments in portfolio companies. The fair value can increase or decrease from either amounts paid to or received from the
investment entity subsidiaries or valuation movements in line with the Group’s valuation policy.
1.4 Significant judgements and estimates
In preparing the consolidated financial statements, estimates and assumptions are made that affect the amounts recorded in the financial statements. The significant judgments
relate mainly to:
The Company’s classification as an Investment Entity under IFRS 10. Management has concluded that the Company continues to meet the definition of an Investment Entity,
as its primary objective is to obtain returns from capital appreciation and investment income, rather than from providing management services. This assessment considers
factors such as the composition of the Group’s portfolio, the nature and purpose of its subsidiaries, and the way performance is evaluated.
The assessment of the Group whether a new subsidiary qualifies as an investment entity under IFRS 10, based on the function the entity performs within the Group.
The Group considers its investment in equity and debt instruments of a portfolio company to constitute a single unit of account. This judgement is based on the fact that
both instruments are economically interdependent and form part of one integrated investment structure. Decisions regarding the acquisition and disposal of the equity and
debt instruments are not taken independently from each other.
The significant estimates mainly concern:
The valuation of the investment portfolio which are measured at fair value through profit or loss. Details of valuation methodologies used and the associated sensitivities are
disclosed in Note 3. Investment portfolio.
The valuation of "defined benefit" pension liabilities.
These judgements and estimates assume that the continuity of the business activities is guaranteed and are made on the basis of the information available at that time. The
estimates may be revised whenever the circumstances on which they are based evolve or when new information becomes available. Actual results may differ from these
judgements and estimates.
26
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
Segment reporting
IFRS 8 Operating Segments requires the identification of segments based on internal records and reports regularly submitted to the key operating decision maker for decisionmaking and performance evaluation. Consequently, the Group divides the consolidated income statement over its three growth dimensions: Core, Anchor and Partnerships. These
dimensions are translated into six segments supplemented by one business services segment. The breakdown of the consolidated income statement is supplemented by a
breakdown of the investment portfolio and investments during the reported period.
The segmental analysis is prepared on the Investment basis. The Investment basis is an APM and the Group believes it provides a more understandable view of performance. For
more information on the Investment basis, see chapter 4. The segment analysis reconciles the Investment Basis with the IFRS basis.
The Core dimension relate to the four investment platforms: Consumer, Healthcare, Smart Industries and Sustainable Cities. Each investment platform is reported as a segment.
Consumer, focusing on companies that respond to the needs and preferences of consumers who consciously choose active, healthy and ecologically responsible lifestyles;
Healthcare, focusing on healthcare providers and patient services, on leading B2B service & software companies and on medical products;
Smart Industries, focusing on companies that excel in their sectors through innovative engineering and intelligent technologies; and
Sustainable Cities, focusing on leading companies in the energy & environment, and construction & materials sector clusters, including chemicals, infrastructure installation
and transport & logistics. Climate change and urbanisation are essential drivers for the growth of companies in these sectors.
In the beginning of the current financial year the Group decided to no longer making any further new investments in the Life Sciences platform. The existing Life Sciences portfolio
will be retained and managed with a view to further maximizing value. Hence, the Life Sciences platform won’t be presented anymore as a separate segment, the Life Sciences
platform will be included in the Business Services and Other segment.
The Anchor dimension and segment comprises the Group’s interest in Gimv Anchor Investments. With Anchor, The Group aims to build long-term strategic partnerships with
leading growth companies. This enables these companies to attract long-term capital to further expand their activities while remaining securely anchored.
The Partnership dimension comprises the Group’s interest in Infravest (segment Infra), which includes the listed company TINC and Tinc Development Partners. Infravest has
helped to stabilise TINC's shareholding structure. Through Infravest, the Group aims to develop and manage a wide range of infrastructure projects in partnership with WorxInvest
and Belfius and contribute to the ongoing upgrading of European infrastructure.
The last segment is the Business Services & Other segment, this segment comprises activities and investments that are not directly attributable to the Group’s main investment
platforms. It primarily includes corporate support functions and shared services (such as finance, legal, HR, IT and governance), central management and holding activities, certain
residual or legacy investments, including the existing Life Sciences portfolio, not aligned with the current platform structure and other non-platform specific income and expenses.
This segment reflects the Group’s corporate infrastructure and central operating costs that are not managed at platform level by the chief operating decision maker.
Additional reporting is provided on a geographic basis in note 2.2. The portfolio result is broken down by geographical area, supplemented by a breakdown of the investment
portfolio and the investments during the reported period.
27
Half-year report 2026
2.1
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
Segment information by platform
Segment information on the consolidated financial statements by platform for the period ended 30 June 2026
Total
Investment
basis
IFRS
adjustments
IFRS total
692
692
15,530
15,530
15,530
15,530
211
-240
-695
-84
-808
-808
-808
-808
-808
6,642
6,910
-268
6,642
79
6,721
6,721
6,721
6,721
6,721
-5,927
15,093
-21,020
-5,235
453
298
-5,452
-5,098
-2,434
-1,431
-4,777
-23,676
2,443
-21,233
-5,341
-26,574
-921
-27,495
8,166
-35,661
183,269
250,277
-67,008
198,799
1,044
1,504
-7,769
-14,932
-12,118
-1,431
-4,777
160,320
2,443
162,763
-5,341
157,422
-921
156,501
8,166
148,335
-100,745
-100,745
87,244
-13,501
3,554
882
899
-8,166
-8,166
-8,166
-8,166
-8,166
82,524
149,532
-67,008
87,244
185,298
1,044
3,554
1,504
-6,887
-14,932
-12,118
-1,431
-3,878
152,154
2,443
154,597
-5,341
149,256
-921
148,335
148,335
Healthcare
Sustainable
Cities
Anchor
10,390
10,390
4,345
4,345
103
103
45,667
60,668
-15,001
45,667
17
-322
-2,038
-861
42,463
42,463
42,463
42,463
42,463
19,893
24,314
-4,421
30,283
26
-587
-3,373
-1,414
24,935
24,935
24,935
24,935
24,935
52,634
68,111
-15,477
56,979
380
7
-712
-1,624
-5,570
49,460
49,460
49,460
49,460
49,460
64,360
75,181
-10,821
64,463
1,077
-456
-2,104
-1,755
61,225
61,225
61,225
61,225
61,225
Consumer
Realised profits/(losses) on disposal of investments
Realised Gains
Realised Losses
Unrealised profits/(losses) on the revaluation of investments
Unrealised Gains
Unrealised Losses
Fair value movements on investment entity subsidiaries
Dividend income
Portfolio result: profit (loss)
Management, director and other fees
Income from investment entity subsidiaries
Other operating income
Services and other goods
Employee benefits - remuneration
LTIP benefits
Amortisation and depreciation
Other operating expenses
Operating profit
Finance income
Profit before financing and income taxes
Finance costs
Profit before tax
Corporate income tax
Net profit for the period
Minority result
Net profit for the period of the group
Infra
Business
Services &
Other
Smart
Industries
For the six months ending 30/06/2026 per platform
(in 1,000 EUR)
28
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
Segment information on the consolidated financial statements by platform for the period ended 30 June 2025
For the six months ending 30/06/2025 per platform
(in 1,000 EUR)
Realised profits/(losses) on disposal of investments
Realised Gains
Realised Losses
Unrealised profits/(losses) on the revaluation of investments
Unrealised Gains
Unrealised Losses
Fair value movements on investment entity subsidiaries
Dividend income
Portfolio result: profit (loss)
Management, director and other fees
Income from investment entity subsidiaries
Other operating income
Services and other goods
Employee benefits - remuneration
LTIP benefits
Amortisation and depreciation
Other operating expenses
Operating profit
Finance income
Profit before financing and income taxes
Finance costs
Profit before tax
Corporate income tax
Net profit for the period
Minority result
Net profit for the period of the group
Consumer
Healthcare
Smart
Industries
1,528
13,892
-12,364
1,528
23
15
-819
-2,530
-367
-2,150
-2,150
-2,150
-2,150
-2,150
38,701
38,701
-7,073
14,962
-22,035
31,628
24
-2,124
-883
-1,675
26,970
26,970
26,970
26,970
26,970
29,932
61,040
-31,108
29,932
123
18
-411
-1,830
-341
27,491
27,491
27,491
27,491
27,491
Sustainable
Cities
Anchor
5,400
5,456
-56
62,009
74,807
-12,798
67,409
109
51
-1,706
-4,416
61,447
61,447
61,447
61,447
61,447
2,611
2,611
2,611
214
-2
-121
2,702
2,702
2,702
2,702
2,702
Infra
Business
Services &
General
Total
Investment
basis
IFRS
adjustments
IFRS total
9,804
9,804
-5,157
55
-5,212
4,647
70
4,717
4,717
4,717
4,717
4,717
118
9,973
-3,269
3,147
-31,303
43
-3,108
579
39
-6,509
-4,632
-1,754
-1,367
-3,581
-19,058
6,945
-12,113
-5,342
-17,455
-278
-17,733
1,335
-19,068
63,878
63,934
-56
55,694
170,514
-114,820
43
119,615
725
489
-9,814
-11,702
-8,553
-1,367
-3,581
85,812
6,945
92,757
-5,342
87,415
-278
87,137
1,335
85,802
-12,607
-12,607
6,026
-6,581
1,224
3,005
562
-1,790
-13
-1,803
468
-1,335
-1,335
-1,335
63,878
63,934
-56
43,087
157,907
-114,820
6,026
43
113,034
725
1,224
489
-6,809
-11,702
-8,553
-1,367
-3,019
84,022
6,932
90,954
-4,874
86,080
-278
85,802
85,802
29
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
Segment information on the assets by platform for the period ended 30 June 2026
Balance at 30/06/2026 per platform (in 1,000 EUR)
Segment assets
Investment portfolio
Investments
Investments in investment entity subsidiaries
Consumer
Healthcare
Smart
Industries
412,324
412,324
503,631
503,631
506,802
506,802
Sustainable
Cities
Anchor
480,109
480,109
277,072
277,072
Infra
Business
Services &
Other
Total
Investment
basis
IFRS
adjustments
IFRS total
95,655
95,655
131,753
131,753
2,407,346
2,407,346
-18,856
-857,792
838,936
2,388,490
1,549,554
838,936
Total
Investment
basis
IFRS
adjustments
IFRS total
Segment information on the assets by platform for the period ended 31 December 2025
Balance at 31/12/2025 per platform (in 1,000 EUR)
Consumer
Healthcare
Smart
Industries
Segment assets
Investment portfolio
Investments
Investments in investment entity subsidiaries
368,721
368,721
502,710
502,710
453,750
453,750
Sustainable
Cities
Anchor
Infra
Business
Services &
Other
418,851
418,851
164,752
164,752
86,398
86,398
125,761
125,761
2,120,943
2,120,943
-7,972
-757,073
749,101
2,112,971
1,363,870
749,101
Germany
France
Rest of
Europe
Other
countries
Total
Investment
basis
IFRS
adjustments
IFRS total
53
53
-15,389
14,136
-29,525
-15,336
543
543
21,349
30,595
-9,246
21,892
10,390
10,390
-629
2,730
-3,359
9,761
1,086
1,086
1,086
15,530
15,530
183,269
250,277
-67,008
198,799
-100,745
-100,745
87,244
-13,501
15,530
15,530
82,524
149,532
-67,008
87,244
185,298
2.2 Segment information by geographic area
Segment information on the portfolio result by geographic area for the period ended 30 June 2026
For the six months ending 30/06/2026 per region (in 1,000 EUR)
The
Belgium Netherlands
Realised profits/(losses) on disposal of investments
Realised Gains
Realised Losses
Unrealised profits/(losses) on the revaluation of investments
Unrealised Gains
Unrealised Losses
Fair value movements on investment entity subsidiaries
Dividend income
Dividend income
199
199
42,364
60,697
-18,333
42,563
4,345
4,345
134,488
141,033
-6,545
138,833
30
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
Segment information on the portfolio result by geographic area for the period ended 30 June 2025
For the six months ending 30/06/2025 per region (in 1,000 EUR)
Realised profits/(losses) on disposal of investments
Realised Gains
Realised Losses
Unrealised profits/(losses) on the revaluation of investments
Unrealised Gains
Unrealised Losses
Fair value movements on investment entity subsidiaries
Dividend income
Portfolio result: profit (loss)
The
Belgium Netherlands
19,572
19,572
33,146
84,530
-51,384
43
52,761
98
98
36,473
44,061
-7,588
36,571
Other
countries
Total
Investment
basis
IFRS
adjustments
IFRS total
Germany
France
Rest of
Europe
44,090
44,146
-56
6,518
28,280
-21,762
50,608
-20,688
9,352
-30,040
-20,688
107
107
-517
91
-608
-410
11
11
762
4,200
-3,438
773
63,878
63,934
-56
55,694
170,514
-114,820
43
119,616
-12,607
-12,607
6,026
-6,581
63,878
63,934
-56
43,087
157,907
-114,820
6,026
43
113,034
Germany
France
Rest of
Europe
Other
countries
Total
Investment
basis
IFRS
adjustments
IFRS total
386,131
386,131
326,184
326,184
184,581
184,581
27,335
27,335
2,407,346
2,407,346
-18,856
-857,792
838,936
2,388,490
1,549,554
838,936
Other
countries
Total
Investment
basis
IFRS
adjustments
IFRS total
211,324
211,324
2,120,943
2,120,943
-7,972
-757,073
749,101
2,112,971
1,363,870
749,101
Segment information on the segment assets by geographic area for the period ended 30 June 2026
Balance at 30/06/2026 per region (in 1,000 EUR)
The
Belgium Netherlands
Segment assets
Investment portfolio
Investments
Investments in investment entity subsidiaries
834,749
834,749
648,366
648,366
Segment information on the segment assets by geographic area for the period ended 31 December 2025
Balance at 31/12/2025 per region (in 1,000 EUR)
The
Belgium Netherlands
Germany
France
Rest of
Europe
Segment assets
Investment portfolio
Investments
Investments in investment entity subsidiaries
673,951
673,951
401,065
401,065
304,235
304,235
15,305
15,305
515,063
515,063
31
Half-year report 2026
Investment portfolio
3.1
Composition
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
The total investment portfolio consists of the following financial assets. A minor 0.6% of the total portfolio value consists of investments in listed companies.
Investment portfolio (in 1,000 EUR)
Direct investments
in equity instruments
in debt instruments
Investments in investment entity subsidiaries
Total
of which listed investments
30/06/2026
31/12/2025
1,549,554
1,162,201
387,353
838,936
2,388,490
14,331
1,363,870
1,090,248
273,622
749,101
2,112,971
16,778
A minor 0.6% of the total portfolio value comprises investments in listed companies (0.8% last year). The direct investments also comprise the valuation of expected earn out
payments amounting to 1.6% of the total investment portfolio (versus 1.1% last year).
At 30 June 2026 the Group has investments in these two listed companies:
Listed companies
Ticker
Stake
in %
Number of
shares
Biotalys
Onward
BTLS
ONWD
6.05%
3.47%
2,749,855
2,411,268
In line with the concentration risk approach, the Group can report that as at the end of June 2026, the investment in Gimv Anchor Investments represents more than 10%, but less
than 15% of the total portfolio value.
32
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
3.2 Evolution of the Direct investments
Evolution direct investments (in 1,000 EUR)
Opening value
Investments
Divestments / repayments
Unrealised gains in fair value
Unrealised losses in fair value
Transfer of direct investments to investment entity subsidiaries
Other movements
Closing value
30/06/2026
31/12/2025
1,363,870
138,215
-36,780
143,338
-60,814
1,726
1,549,554
1,623,346
93,785
-147,015
224,316
-117,937
-260,276
-52,348
1,363,870
The main direct investments are add-on investments in Anchor (AN; BE) and various Life Sciences investments. The main divestments during the financial year were Les Psy Réunis
(HC; GE), ALT (SI; NL), Baas/Verkley (SC; NL) and Anchor (AN; BE). The in- and divestments in Anchor comprised of shareholder loans used to finance the investment in Azelis (AN;
BE). The significant contributors to the unrealized gains were Hemink (SC; NL), Metis (SI; NL), Baas/Verkley (SC; NL), Televic (SI; BE) and Picot (SI, BE). The largest contributors to
the unrealised losses were Laser 2k (SI; GE), ERS (SI; GE), and Anchor (AN; BE). The other movements mainly comprise an outstanding escrow following the exit of ALT (SI; NL).
During the previous fiscal year the main investments were in in Infravest (Infra; BE), Picot (SI; BE) and E.Gruppe (HC; GE). The main divestments were Spineart (HC; BE), Itineris
(SC; BE), Joolz (CO; NL) and Imcheck (LS; BE). The significant contributors to the unrealized result were Techinfra (SC; GE), Baas/Verkley (SC; NL), GSDI (SC; FR), Infravest (Infra;
BE) and Les Psy Réunis (HC; GE). During the first semester of the previous financial year the transfer of the investments already held by the Group at the end of 31 March 2025 to
the investments in investment entity subsidiaries took place, the transfer was done at fair value.
The following table reconciles the investment amounts as presented in the cash flow statement with the movement schedule.
Reconciliation to consolidated cash flow statement (in 1,000 EUR)
Direct investments according to cash flow statement
Direct investments according to movement schedule
Difference to explain
Investment netted with partial divestment
Vendor loan granted related to sale of portfolio companies
30/06/2026
31/12/2025
137,143
138,215
1,072
1,072
108,362
93,785
-14,577
14,577
33
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
3.3 Evolution of the investments in investment entity subsidiaries
Evolution investments in investment entity subsidiaries (in 1,000 EUR)
Opening value
Amounts paid to investment entity subsidiaries
Amounts received from investment entity subsidiaries
Fair value movements on investment entity subsidiaries
Transfer of direct investments to investment entity subsidiaries
Other increase (+) or decrease (-)
Closing value
30/06/2026
31/12/2025
749,101
2,468
87,244
123
838,936
428,625
4,125
55,904
260,276
170
749,101
Amounts paid mainly reflect the financing of the operating expenses and investments done by the investment entity subsidiaries in the underlying portfolio companies.
3.4 Classification of financial instruments and fair value hierarchy
The following table compares the carrying amounts and the fair values of the Group’s financial instruments.
The fair values of the Group’s financial assets and liabilities not measured at fair value are not materially different from their carrying amounts. The carrying amounts of cash and
cash equivalents, trade and other receivables, and trade and other payables approximate their fair value due to their short-term nature.
Financial liabilities measured at amortised cost are included in the hierarchy disclosure where fair value is disclosed. The fair value of the bonds is determined based on quoted
market prices at the reporting date.
The following section describes the valuation techniques applied in accordance with IFRS 13 to determine the fair value of unlisted Level 3 investment portfolio assets.
34
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
For the reported period ending 30 June 2026
Carrying amounts
Classification (1,000 EUR)
Investment portfolio
Direct investments
Investments in investment entity subsidiaries
Fair value hierarchy
30/06/2026
IFRS 9 Classification
Level 1
Level 2
Level 3
2,388,490
1,549,554
Fair value through profit and loss
Fair value through profit and loss
14,331
14,331
2,374,159
1,535,223
838,936
Fair value through profit and loss
838,936
Cash and cash equivalents
131,221
Amortized cost
Marketable securities
Trade receivables
Financial liabilities - bonds
Trade payables
897
358,827
1,204
Fair value through profit and loss
Amortized cost
Amortized cost
Amortized cost
During the first semester of financial year 2026 no transfers in hierarchy occurred.
For the financial year ended 31 December 2025
Carrying amounts
Classification (1,000 EUR)
Investment portfolio
Direct investments
Investments in investment entity subsidiaries
Cash and cash equivalents
Marketable securities
Trade receivables
Financial liabilities - bonds
Trade payables
Fair value hierarchy
331/12/2025
IFRS 9 Classification
Level 1
Level 2
Level 3
2,112,971
1,363,870
749,101
172,868
150,534
442
355,855
1,891
Fair value through profit and loss
Fair value through profit and loss
Fair value through profit and loss
Amortized cost
Fair value through profit and loss
Amortized cost
Amortized cost
Amortized cost
16,778
16,778
150,534
2,096,194
1,347,093
749,101
During the financial year 2025 no transfers in hierarchy occurred.
35
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
3.5 Valuation methods applied for level 3 and sensitivity on fair value
The following table explains the various measurement methods applied pursuant to IFRS 13 to determine the fair value of non-listed (level 3) shareholdings in the investment
portfolio as well as the inputs, the sensitivities applied and the impact of those sensitivities to the unobservable inputs.
All numbers in the table below are based on the Investment basis consolidated statements, see chapter 5 ‘Note half year result’ for more details on the Investment basis and the
reconciliation with the IFRS statements. The sensitivity analysis is based on the non-listed investments and applies a transparent approach for investments held via Gimv Anchor
and Infravest. The respective investments in the listed companies Azelis and TINC are not included in this sensitivity analysis. Other investments held by Gimv Anchor and by
Infravest are included in their respective valuation method.
Valuation method
Description
Significant unobservable inputs
Discounted cash flow
Applied for investments in companies for which a
predictable, solid and well-founded business plan is
available and that constitute 3% or more of the total
portfolio’s fair value.
This method may be applied independently or
alongside other valuation techniques serving as
benchmarks. Fair value is estimated by deriving the
present value of the investment using reasonable
assumptions regarding anticipated future cash flows (or
expected earnings, when used as a proxy) and terminal
value, and an appropriately risk-adjusted discount rate
reflecting the investment's inherent risks. The discount
rate is estimated with reference to the market risk-free
rate, a risk-adjusted premium, and relevant information
pertaining to the particular investment or market sector.
The weighted average cost of capital (or
WACC) is considered unobservable input
The terminal value based on a long-term
growth rate (or LTGR) is considered
unobservable input
Fair value 30/06/2026
(1,000 EUR)
589,994
(31/12/2025: n/a)
Sensitivities on key
unobservable input
Increase of 1% in the
WACC
Decrease of 1% in the
WACC
Increase of 0.5% in
the LTGR
Decrease of 0.5% in
the LTGR
Fair value impact
of sensitivities
(1,000 EUR)
-61,723
77,337
31,273
-27,885
36
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Fair value impact
of sensitivities
(1,000 EUR)
Valuation method
Description
Significant unobservable inputs
Fair value 30/06/2026
(1,000 EUR)
Market multiples
Applied for investments in companies with identifiable,
sustainable streams of revenue or earnings that can
be considered maintainable, and for which comparable
public companies (peers) or relevant market
transactions can be determined.
Public peers are selected based on similar
characteristics such as industry sector and, where
possible, alignment in business model, growth trajectory
and risk profile.
The calibration technique is used to capture distinctions
between the company and its listed peers.
Earnings multiples, which are most common, are
applied to the earnings of the company to determine
the enterprise value.
The most frequently used measure is earnings before
interest, tax, depreciation and amortisation (“EBITDA”).
Earnings are usually obtained from portfolio company
management accounts up to the preceding quarter
end, while also considering forecast earnings and the
view on sustained earnings.
Used for recent investments in unlisted companies (only
for a limited period following the transaction date).
Applied for investments in companies without
significant earnings or cash flows.
Applied for (i) investments in Gimv Anchor Investments
and Infravest not allocatable to the other methods; (ii)
investments in third-party funds (not managed by Gimv)
and (iii) investments in co-investment partnerships.
In exceptional cases, a different valuation technique is
applied with the aim of better reflecting the fair value of
the investment and applied based on an external report
or signed agreement, for example: imminent sale, IPO,
post-exit payments.
The calibration-effect is considered
unobservable input
1,087,696
(31/12/2025: 1,207,675)
Increase by 10% in the
calibration-effect
Decrease by 10% in
the calibration-effect
-25,123
(31/12/2025:-28,060)
25,437
(31/12/2025: 28,060)
The transaction price of the most recent
transaction is considered unobservable
input
451,292
(31/12/2025: 584,001)
Fair value based on fund reporting is
considered unobservable input
53,463
(31/12/2025: 267,420)
Fair value is considered unobservable
input
46,903
(31/12/2025: 45,070)
Increase of 10% in the
fair value
Decrease of 10% in
the fair value
Increase of 10% in the
fair value
Decrease of 10% in
the fair value
Increase of 10% in the
fair value
Decrease of 10% in
the fair value
45,129
(31/12/2025: 58,400)
-45,129
(31/12/2025: -58,400)
5,246
(31/12/2025: 26,742)
-5,246
(31/12/2025: -26,742)
4,690
(31/12/2025: 4,507)
-4,690
(31/12/2025: -4,507)
Price of a recent
transaction
Fair value derived
from the value of the
fund's net assets
Other (*)
Total level 3
Sensitivities on key
unobservable input
Financial statements
2,228,348
(31/12/2025: 2,104,165)
(*) In some of our portfolio companies, certain future payments are linked to milestones. These expected payments are factored in based on probabilities and taking into account our internal cost of capital.
37
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
Cash and marketable securities
Cash and cash equivalents include cash held either in cash, on bank deposits with a maturity of up to six months or invested in liquid products with a maturity of up to three
months. These products are used to meet short-term cash needs and are not subject to valuation fluctuations and can be converted into cash at any time without paying an
additional fee. These products are recognised in the statement of financial position at nominal value including accrued interest not yet received.
Marketable securities are investment instruments with a maturity of more than three months and may be subject to valuation fluctuations. The changes in valuation of these
securities are recognised in the statement of profit or loss. They are presented in the statement of financial position at fair value, including accrued interest not yet received. These
securities can be converted into cash liquidity without significant compensation.
Following the significant investments in Anchor and the upcoming repayment of the EUR 75,000 thousand bond, the Group converted its marketable securities into cash
equivalents.
Cash and marketable securities (in 1,000 EUR)
30/06/2026
31/12/2025
Cash and cash equivalents
Bank deposits
Short term investments
Cash and other equivalents
131,221
2
9,942
121,277
172,868
95,831
34,846
42,192
Marketable securities
Total
131,221
150,534
323,402
38
Half-year report 2026
Issued capital, issue premium and reserves
5.1
Issued capital and issue premium
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
The issued capital, the issued shares and issue premium did not change during the first semester of the financial year 2026. At the end of June 2026, the issued capital amounts
to EUR 345,460 thousand represented by 36,810,933 fully paid-up ordinary, no-par-value shares. All shares have the same rights and accounting par value. Gimv has not issued
any securities which, if exercised or converted, would increase the number of shares.
Capital and share premium (in 1,000 EUR)
30/06/2026
31/12/2025
Number of issued shares at start of period
Changes during the period
Number of issued shares at end of period
Capital at start of the period
Changes during the period
Cost of capital increase
Capital at end of the period
Share premium at start of the period
Changes during the period
Share premium at end of the period
36,810,933
36,810,933
345,460
345,460
369,449
369,449
35,767,300
1,043,633
36,810,933
335,554
9,905
345,460
337,568
31,881
369,449
5.2 Own shares
Gimv did not held own shares at the end of the previous financial year. In the course of the first semester of current financial year, Gimv purchased 75,000 shares of which 68,314
shares were sold to employees.
Treasury shares
Number of own shares at start of period
Changes during the period
Number of own shares at end of period
Own shares: capital size at start of period
Changes during the period
Own shares: capital size at end of period (in 1,000 EUR)
30/06/2026
31/12/2025
6,686
6,686
130
130
14,299
-14,299
269
-269
39
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
Dividend
In June 2026, the ordinary general meeting resolved to pay a dividend for the financial year 2025 in the amount of EUR 71,781 thousand (EUR 1.95 per share). The dividend was
paid out of the reserves.
In line with the dividend policy the Group has decided to not pay an interim dividend.
Proposed and distributed dividends (in 1,000 EUR)
30/06/2026
31/12/2025
71,781
71,781
1.95
92,995
92,995
2.60
n/a
n/a
71,781
1.95
Declared and paid out during the year
Gross amount
Dividend per share
Proposed for approval by AGM
Proposed gross dividend per share (in EUR)
Non-current and current financial debts
The non-current and current financial debts consist mainly of bonds totaling a nominal value of EUR 350,000 thousand of which EUR 75,000 thousand has a remaining maturity
until July 2026 and has been fully repaid. The interest liability on the bonds amounts to EUR 8,827 thousand. The market value of these bonds amounts to EUR 351,838 thousand.
The nominal EUR 100,000 thousand bond matures in March 2029 and the nominal EUR 175,000 thousand bond matures in July 2031.
Besides these bonds, Gimv also has a lease obligation of EUR 9,545 thousand. This amount is the result of the IFRS 16 Leases standard.
Remaining term
Financial debt as per 30/06/2026 (in 1,000 EUR)
< 1 year
1 to 5 years
5 years
Total
Bonds
Lease liabilities (IFRS 16)
Total
83,827
1,636
85,463
100,000
7,909
107,909
175,000
175,000
358,827
9,545
368,372
Remaining term
Financial debt as per 31/12/2025 (in 1,000 EUR)
< 1 year
1 to 5 years
5 years
Total
Bonds
Lease liabilities (IFRS 16)
Total
80,855
1,687
82,542
100,000
8,623
108,623
175,000
175,000
355,855
10,311
366,166
40
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
LTIP liabilities, LTIP benefits and other provisions
LTIP liabilities
The Group operates several long‑term incentive plans (LTIP) for members of the executive committee and a significant part of the Gimv team. These plans are designed to align
participants’ interests with long‑term value creation and are accounted for in accordance with IFRS 2 Share‑based Payment and, where applicable, IAS 19 Employee Benefits,
depending on their characteristics. The Group does not operate any equity settled share based payment arrangements.
Cash settled LTIPs are recognised over the relevant vesting periods, based on the best estimate of the amount expected to be paid, and are remeasured at each reporting date,
with changes recognised in profit or loss within LTIP benefits. Employer social security charges, where applicable, are accrued consistently with the measurement of the underlying
LTIP liability.
Historical co‑investment structures (earn‑outs)
Under historical co‑investment structures, beneficiaries are entitled to earn‑out payments linked to the performance of certain investment portfolios. These arrangements are no
longer granted but continue to give rise to liabilities in respect of existing vintages.
A liability is recognised for expected future payments, measured based on:
realised cash proceeds already generated by the underlying portfolios; and
estimates of additional amounts payable based on the fair value of unrealised investments at the reporting date.
Movements in these liabilities are recognised in LTIP benefits and payments to beneficiaries result in a reduction of the liabilities.
Other provisions
Provisions are recognised when the Group has a present legal or constructive obligation as a result of a past event, an outflow of economic resources is probable, and a reliable
estimate can be made. Provisions are measured at the best estimate of the expenditure required to settle the obligation, discounted where the effect of the time value of money
is material. The unwinding of the discount is recognised in finance costs.
Provisions mainly relate to litigation, claims and warranties. Pension obligations are disclosed in Note 12. Employee benefit in the previous year annual report.
41
Half-year report 2026
8.1
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
LTIP liabilities as per 30 June 2026
During the first semester of the current financial year a total amount of 1,959 thousand EUR was paid to the beneficiaries of the various LTIP plans (previous financial year
40,891 thousand EUR).
Overview of LTIP and historical co-investment structures (CIV) (in 1,000 EUR)
Liabilities for historical CIV structures
Vintage 2013-2015
Vintage 2016-2017
30/06/2026
11,930
3,380
8,550
31/12/2025
12,190
2,668
9,522
Paid
1,435
1,435
Change
1,175
712
462
Liabilities LTI Plans
Vintage 2018-2020
Vintage 2021-2023
Vintage 2024 - Gimv share plan 2024
Vintage 2024 - Gimv share plan 2025
45,723
32,212
12,583
685
242
35,304
23,754
11,065
485
524
190
319
15
10,943
8,649
1,837
215
242
Total
Non current liabilities
Current liabilities
57,652
56,913
740
47,494
46,166
1,328
1,959
12,117
8.2 Portfolio‑based LTIP vintages (2018–2020 and 2021–2023)
Under these LTIP arrangements, participants are entitled to a cash bonus based on a predefined share of the cash value created on investment portfolios built up during specific
multi‑year investment periods (“vintages”). Entitlements arise only after recovery of the invested capital.
The plans are cash‑settled, vest over the life of the underlying portfolios and are subject to good‑ and bad‑leaver provisions. Amounts are recognised as a liability and measured
at fair value based on realised proceeds and estimates of future value creation.
Gimv Share LTIP
The Gimv Share LTIP is a cash‑settled long‑term incentive plan linked to the growth in market capitalisation and net asset value of the Company over a rolling three‑year
performance period, above a pre-defined hurdle rate. Vesting occurs progressively over the vesting period, subject to continued service and performance conditions.
Liabilities are measured based on the expected cash settlement amount, taking into account realised gains and estimates of future performance.
Gimv Anchor LTIP
The Gimv Anchor LTIP is a cash‑settled long-term incentive plan linked to the growth in net asset value of specific long‑term (“anchor”) portfolio companies on a deal‑by‑deal
basis, above a predefined hurdle rate. Vesting is subject to service conditions and performance over a multi‑year period.
Liabilities are measured based on the expected cash settlement amount, taking into account realised gains and estimates of future performance.
42
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
8.3 Other provisions as per 30 June 2026
The provision for litigation and warranties did not change during the first semester of the financial year. The provision relates to the remediation of a site that was part of a
historical investment fully divested several years ago. The provisioned amount is still being considered as appropriate based on the information available as per 30 June 2026.
Other provisions 30/06/2026 (in 1,000 EUR)
Opening Balance
Additional provisions (+)
Use of provisions (-)
Reversal of unused provisions (-)
Closing balance
Litigation or
warranties
Remeasurement
pension plans
Total
2,500
2,500
-566
3
-563
1,934
3
1,937
Portfolio result
The portfolio result comprises the gains and losses from the investment portfolio. During the first six months of the financial year , the portfolio result amounted to EUR 185,298
thousand, mainly due to the positive valuation result of the direct investments and the fair value movement of the investments in investment entity subsidiaries.
Gains and losses from the investment portfolio (in 1,000 EUR)
Direct investments
Realised gains/(losses) on disposal of investments
Realised gains on disposal of investments
Realised losses on disposal of investments
Unrealised gains/(losses) on the revaluation of investments
Unrealised gains on the revaluation of investments
Unrealised losses on the revaluation of investments
Fair value movements on investment entity subsidiaries
Dividend income
Total
30/06/2026
30/06/2025
98,054
15,530
15,530
82,524
149,532
-67,008
87,244
185,298
106,965
63,878
63,934
-56
43,087
157,907
-114,820
6,026
43
113,034
43
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
- Operating expenses
Operating expenses include services and other goods, employee benefits - remuneration, LTIP benefits, depreciation and amortisation, and other operating costs. For more
information on LTIP, see Note 10 and the remuneration policy in the previous year’s annual report. The other operating expenses mainly consist of non-recoverable VAT.
The recurring operating expenses are 20% higher than in the first semester of the financial year 2025. The increase can be explained by (i) the impact of decision of the Group
to no longer prospect for new Life Sciences investments, (ii) new employees, (iii) redundancy payments, and (iv) inflation impact and merit increases. The other recurring operating
expenses are in line with the previous period.
The LTIP benefits are the payments made and accrued liabilities for the various active LTIPs and co-investment structures.
Operating expenses (in 1,000 EUR)
30/06/2026
30/06/2025
Services and other goods
Employee benefits - remuneration
Amortisation and depreciation
Other operating expenses
Recurring operating expenses
LTIP benefits
Total operating expenses
6,887
14,932
1,431
3,878
27,128
12,118
39,246
6,809
11,702
1,367
3,019
22,897
8,553
31,450
- Earnings per share
Earnings per share are obtained by dividing the net result attributable to the holders of ordinary shares of the parent company by the weighted average number of shares
outstanding during the financial year.
The diluted net earnings per share is equal to the net earnings per share because, as of 30 June 2026, no instruments exist that have a dilutive effect on the holders of ordinary
shares.
Net result per share (in 1,000 EUR)
30/06/2026
30/06/2025
Net result of the period, share of the group
Weighted average number of shares
Earnings (loss) per share (in EUR)
148,335
36,803,023
4.03
85,802
36,807,107
2.33
Net result of the period, share of the group
Weighted average number of shares
Impact dilution effect
Adjusted weighted average number of shares
Diluted earnings (loss) per share (in EUR)
148,335
36,803,023
36,803,023
4.03
85,802
36,807,107
36,807,107
2.33
44
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
- Subsidiaries, investment entities and active portfolio companies
12.1 Consolidated subsidiaries
For these fully consolidated subsidiaries the beneficial interest percentage corresponds to the percentage of voting rights held by the Group.
Name of subsidiary
Registered office
Adviesbeheer Gimv Consumer 2013
Adviesbeheer Gimv Consumer 2016
Adviesbeheer Gimv Group 2013
Adviesbeheer Gimv Group 2016
Adviesbeheer Gimv Health Care 2013
Adviesbeheer Gimv Health Care 2016
Adviesbeheer Gimv Sustainable Cities 2013
Adviesbeheer Gimv Sustainable Cities 2016
Adviesbeheer Gimv Smart Industries 2013
Adviesbeheer Gimv Smart Industries 2016
Dutch Participants Sub-Holding 2013 BV
Dutch Participants Holding 2013 BV
Dutch Participants Sub-Holding 2016 BV
Dutch Participants Holding 2016 BV
Gimv France Participations
Gimv Germany Holding
Gimv Investments Consumer Netherlands 2016
Gimv Investments Consumer Netherlands 2013
Gimv Investments H&C Netherlands 2013
Gimv Investments H&C Netherlands 2016
Gimv Investments Sustainable Cities Netherlands 2013
Gimv Investments Smart Industries Netherlands 2013
Gimv Investments Smart Industries Netherlands 2016
Gimv Nederland Holding
Gimv-XL
Antwerp, Belgium
Antwerp, Belgium
Antwerp, Belgium
Antwerp, Belgium
Antwerp, Belgium
Antwerp, Belgium
Antwerp, Belgium
Antwerp, Belgium
Antwerp, Belgium
Antwerp, Belgium
The Hague, The Netherlands
The Hague, The Netherlands
The Hague, The Netherlands
The Hague, The Netherlands
Paris, France
München, Germany
The Hague, The Netherlands
The Hague, The Netherlands
The Hague, The Netherlands
The Hague, The Netherlands
The Hague, The Netherlands
The Hague, The Netherlands
The Hague, The Netherlands
The Hague, The Netherlands
Antwerp, Belgium
Registration number
Beneficial interest (%)
Changes to previous year
BE518.892.392
BE649.473.594
BE515.977.741
BE649.467.260
BE518.890.018
BE649.474.782
BE518.894.273
BE649.474.188
BE518.893.085
BE649.472.705
59420286
59418583
66483042
66478839
840 172 910
HRB 269510
65881702
62731521
57093156
68071167
59482583
65423445
68071272
27127858
BE820.802.914
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
45
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
12.2 Investment entities
The Gimv Core LTIP 2024 plan is a portfolio based LTIP for vintage 2024-2027, however the amounts are reflected in the fair value measurement of investments in investment entity
subsidiaries. In the Investment basis consolidated financial statements, the corresponding amount (for a total of 16,971 thousand EUR) is presented within non‑controlling interests
rather than LTIP liability. More information on the Core LTIP 2024 can be found in the remuneration report – long term incentives included in previous year’s annual report.
The beneficial interest percentage corresponds to the percentage of voting rights held by the Group. The percentage may vary in line with the number of participants added or
leaving during the period.
Name of investment entity
Registered office
Registration number
Beneficial interest (%)
Changes to previous year
Gimv 2024 Holding
Gimv 2024 NL Poolco
Gimv 2024 Poolco
Gimv Consumer Invest 2024
Gimv Healthcare Invest 2024
Gimv Life Sciences Invest 2024
Gimv Smart Industries Invest 2024
Gimv Sustainable Cities Invest 2024
Antwerp, Belgium
BE1019.840.182
99.9%
0.0%
Antwerp, Belgium
Antwerp, Belgium
Antwerp, Belgium
Antwerp, Belgium
Antwerp, Belgium
Antwerp, Belgium
Antwerp, Belgium
BE1019.841.568
BE1019.842.954
BE1019.844.241
BE1019.845.924
BE1019.848.694
BE1019.850.575
BE1019.852.159
16.0%
8.6%
99.9%
99.9%
99.9%
99.9%
99.9%
-18.1%
6.5%
0.0%
0.0%
0.0%
0.0%
0.0%
12.3 Overview of the active portfolio
The following table is an overview of all active investments (majority and minority) directly and indirectly (via investment entities) held by the Group. Each investment is valued at
fair value according to IFRS 9. Next to the name of the investee group, the table shows the name and the unique company ID of the subsidiary in which the Group is invested in.
The beneficial interest mentioned in the table is the stake held in the investee company.
Name of investee group
Name of subsidiary
Registered office
Platform: Consumer
Agrobiothers
Alpine
Blendwell
Bugaboo
Curana
Groupe Delineo
La Comtoise
Lupine
Olyn
Pet Invest
AHP Holding BV
Blendwell Food Group B.V.
GES Investments BV
Curana Holding
Financière LGN
Financière de l'Echourgnac
Bright Light GmbH
Olyn Management
Cuisery, France
Utrecht, The Netherlands
Giessen, The Netherlands
The Hague, The Netherlands
Ardooie, Belgium
Paris, France
Paris, France
München, Germany
Neuilly-sur-Seine, France
Registration number
Beneficial interest %
Changes to previous year
834 423 162
97 508 985
69 247 668
94 990 077
BE 1010.918.954
832 998 181
843 848 698
HRB 296654
893 683 425
57.6%
96.5%
70.6%
4.8%
94.0%
32.5%
58.5%
67.7%
38.0%
0.0%
-0.1%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
-10.1%
46
Half-year report 2026
At a glance
Message from the CEO
Name of investee group
Name of subsidiary
Registered office
Quality Guard
Sofatutor
The Spice Factory
The Wallfashion House
Food Safety Group BV
EdTech Holding
TSF Holding SRL
The Wallfashion House
Combining Intelligence
Activities
Note half-year results
Financial statements
Registration number
Beneficial interest %
Changes to previous year
Roeselare, Belgium
Berlin, Germany
Braine-l'Alleud, Belgium
Tielt, Belgium
BE 1029.462.582
HRB 112531
BE 1020.542.443
BE 0745.385.810
32.7%
0.2%
83.5%
34.2%
-0.6%
0.0%
-0.3%
0.0%
Platform: Healthcare
Ambulantis
Apraxon
Arseus Medical Group
Bio-Connection
Equine Care Group
France thermes
ILC
Les Psy Réunis
Awelando (former Liveo Gruppe)
MVZ Holding
Novicare
SGH Medical Pharma
Spineart
Platform: Life Sciences
Biotalys
Complement Therapeutics
Exciva
FIRE1
ImmunOs Therapeutics
Kinaset Therapeutics
Kivu Bioscience
Mediar Therapeutics
Onera Health
ONWARD
Paleo
Precirix
Topas Therapeutics
Ambulantis BSW GmbH
Apraxon Holding
Medcare Partners
BioConnection Investments
ECG Fortuna Sarl
Codex 324 Holding
LibRT SAS
Les Psy Réunis
Liveo Holding GmbH
MVZ Holding AG
Novicare Zorggroep Holding BV
MXG
Spineart SA
Berlin, Germany
Hofbieber, Germany
Bornem, Belgium
The Hague, The Netherlands
Luxembourg, Luxembourg
Paris, France
Le Mans, France
Anières, Switzerland
Mannheim, Germany
Zug, Switserland
Best, The Netherlands
Lyon, France
Plan-Les-Quates, Switserland
HRB141703
HRB121220
BE 677.862.724
85 610 658
RCS B301286
832 074 017
933 956 468
CHE 311740605
HRB 755223
CHE 114678485
98 041 002
834 427 429
CHE 112355249
65.0%
70.0%
52.3%
58.9%
18.6%
67.9%
69.3%
0.0%
67.9%
51.0%
82.4%
45.1%
45.4%
0.0%
0.0%
0.0%
0.5%
0.0%
0.0%
0.0%
-56.5%
0.0%
0.0%
0.0%
0.0%
0.0%
Biotalys NV
Complement Therapeutics GmbH
Exciva GmbH
Foundry Innovation & Research 1
Immunos Therapeutics AG
Kinaset Theraputics Inc.
Kivu Biosciences Inc.
Mediar Therapeutics Inc.
Onera Technologies BV
Onward Medical BV
Paleo BV
Precirix NV
Topas Therapeutics GmbH
Sint-Denijs-Westrem, Belgium
München, Germany
Heidelberg, Germany
Dublin, Ireland
Schlieren, Switserland
Medfield, USA
Dover, USA
Cambridge, USA
Eindhoven, The Netherlands
Lausanne, Switserland
Diest, Belgium
Jette, Belgium
Hamburg, Germany
BE 508.931.185
HRB 281972
HRB 725941
535014
CHE 456329046
7953581
4277380
7197945
68 559 690
CHE 64598748
BE 756.986.614
BE 564.736.473
HRB 129330
6.1%
11.5%
15.0%
6.0%
11.7%
14.5%
10.9%
7.6%
11.6%
3.5%
6.8%
8.6%
11.0%
1.3%
-0.1%
4.1%
0.0%
0.0%
-6.4%
1.4%
0.0%
0.0%
-1.9%
0.0%
0.0%
0.0%
Platform: Smart Industries
Alro Group
ALT Technologies
Metis
Alro International
Advanced Safety Technologies
Metis Investments
Dilsen-Stokkem, Belgium
Utrecht, The Netherlands
Eindhoven, The Netherlands
BE 729.709.917
68 218 737
42 045 544
75.0%
0.0%
76.5%
0.0%
-66.7%
11.3%
47
Half-year report 2026
At a glance
Message from the CEO
Name of investee group
Name of subsidiary
Registered office
Arplas
Citymesh
ERS
Laser 2000
Picot
RoboJob
Smart Battery Solutions
SMG
Televic
Variass
Variotech
WDM-Deutenberg Group
Witec
Advanced Joining Technologies
Citymesh Holding
Silicon Hill Holding
L2K
Stachel NV
RoboJob Group NV
Smart Battery Solutions
Iller Valley GmbH
Danver NV
Variass Investments
Kap Nordhorn Holding GmbH
WDM Deutenberg Holding GmbH
Witec Investments
Platform: Sustainable Cities
Acceo
Baas/Verkley
Castelein Sealants
E.Gruppe
Fronnt
GSDI
Hemink
Projective Group
Techinfra
Tibbloc
Combining Intelligence
Activities
Note half-year results
Financial statements
Registration number
Beneficial interest %
Changes to previous year
Amersfoort, The Netherlands
Oostkamp, Belgium
Germering, Germany
Wessling, Germany
Sint-Eloois-Winkel, Belgium
Heist-op-den-Berg, Belgium
Kleinostheim, Germany
Vöhringen, Germany
Izegem, Belgium
The Hague, The Netherlands
Nordhorn, Germany
Gros Pankow, Germany
Stadskanaal, The Netherlands
65 528 247
BE 1012.153.923
HRB 283391
HRB 239577
BE 677.778.689
BE 1019.308.365
HRB 11439
HRB 21142
BE 737.989.955
85 898 449
HRB 218144
HRB 12104
89 447 174
0.0%
23.4%
77.0%
75.0%
29.5%
42.0%
58.9%
78.8%
40.0%
0.0%
82.0%
26.5%
60.0%
-60.0%
0.0%
0.0%
0.0%
0.2%
0.0%
0.0%
0.0%
0.0%
-82.5%
0.0%
0.0%
0.0%
Acceo Group
Konnektor Investments
CS Topco
E.Gruppe Holding
Cristallo Topco
GSDI Covering Holding
HRGS Holding BV
Projective NV
Techinfra Holding GmbH
Tibbco SAS
Gémenos, France
Drachten, The Netherlands
Antwerp, Belgium
Rheinau, Germany
Antwerp, Belgium
Massy, France
Holten, The Netherlands
Machelen, Belgium
München, Germany
Paris, France
822 110 433
81 990 669
BE 1003.053.145
HRB726186
BE 787.628.419
907 722 581
97 693 944
BE 885.932.969
HRB 273904
840 172 910
4.7%
61.1%
51.0%
76.4%
59.6%
66.0%
67.6%
25.2%
75.1%
79.6%
0.0%
0.0%
0.0%
-0.5%
-0.3%
0.9%
-1.5%
0.0%
0.0%
0.0%
Infrastructure
Infravest
DG Infra Yield
Infravest
DG Infra Yield Comm.V
Antwerp, Belgium
Antwerp, Belgium
BE 1011.576.376
BE 0833.921.767
40.8%
4.5%
0%
0%
Anchor
Anchor
Gimv Anchor Investments BV
Antwerp, Belgium
BE 1020 386 451
75.0%
0.0%
Changes in composition
The Group divested its shareholding in the following companies: Les Psy Réunis (HC; GE) ALT (SI; NL) and Arplas (SI; NL). The merger of Variass into AME, renamed to Metis
(SI; NL), was officially finalized in the first semester of the current financial year.
Other changes in the beneficial interest are the result of add-on investments, investment rounds without participation of the Group, continuation exits or partial divestments.
48
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
-
Principal risk factors
The half-year report provides an update on the Group’s strategy, business performance and market environment, all of which remain relevant to its overall risk profile. The principal
risks and uncertainties affecting the Group and the achievement of its strategic objectives, as disclosed in Note 23 of the Annual Report 2025, remain materially unchanged.
The Group continues to operate in an environment characterised by economic uncertainty, geopolitical tensions, inflationary pressures, evolving financing conditions and ongoing
volatility in financial markets. These factors may affect the performance of portfolio companies, investment and divestment activity levels and overall market conditions.
Key areas of continued focus include the performance of the portfolio, the ability to attract and retain talent, cyber security risks and sustainability-related risks within the portfolio.
The Group continuously reviews its principal and emerging risks, together with the associated mitigation measures. While these risks are currently expected to remain broadly
unchanged during the second half of the financial year, they continue to be closely monitored and may evolve in response to changing market and operating conditions.
-
Events after the balance sheet date
The valuation of our portfolio is based on market multiples as at the end of June 2026. Since then, we have closely followed the evolution of the stock markets. To date, we
have not noticed any evolution in market multiples that indicates that our valuation should be adjusted.
On July 5 2026, Gimv repaid 75 mio EUR of its outstanding bonds, bringing the total amount of outstanding bonds to 275 mio EUR.
Mid August, Spineart announces that the BAGUERA® C cervical disc has received FDA approval for 1 and 2 contiguous levels, expanding access in the United States to a
motion-preserving solution for patients suffering from cervical disc disease. This news might have a positive impact on the future valuation of Spineart.
In August, Gimv sold its stake in the Swiss group of Medical Practices MVZ Holding without impact on the Net Asset Value.
Gimv creates the function of “Chief Digital Transformation” at the level of its executive committee. Meanwhile, this position has been filled with an external international
profile. The new member of the executive committee will be presented later.
Tom Van de Voorde, Platform Head of Smart Industries, has decided to leave Gimv. We want to thank Tom for 19 years of fruitful collaboration and Building Leading
Companies together. We wish him all the best with his future endeavours. Information regarding the succession will be communicated later.
49
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements
Statutory auditor’s report
STATUTORY AUDITOR’S REPORT TO THE BOARD OF DIRECTORS OF GIMV NV ON THE REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE
SIX-MONTH PERIOD ENDED 30 JUNE 2026.
Introduction
We have reviewed the accompanying interim consolidated statement of financial position of Gimv NV as of 30 June 2026 and the related interim consolidated statement of profit
and loss and other comprehensive income, interim consolidated statement of changes in equity and interim consolidated cash flow statement for the six-month period then
ended, as well as the explanatory notes. The Board of Directors is responsible for the preparation and presentation of these condensed interim consolidated financial statements
in accordance with IAS 34 “Interim Financial Reporting”, as adopted by the European Union. Our responsibility is to express a conclusion on these condensed interim consolidated
financial statements based on our review.
Scope of review
We conducted our review in accordance with International Standard on Review Engagements 2410, “Review of Interim Financial Information Performed by the Independent Auditor
of the Entity”. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical
and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not
enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
Conclusion
Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed interim consolidated financial statements are not prepared,
in all material respects, in accordance with IAS 34 “Interim Financial Reporting”, as adopted by the European Union.
Antwerp, 2 September 2026
BDO Bedrijfsrevisoren BV
Statutory auditor
Represented by Veerle Catry*
*
Acting for a company
50
Half-year report 2026
At a glance
Message from the CEO
Combining Intelligence
Activities
Note half-year results
Financial statements